Whitepaper: Profiling oncology candidates
Profiling oncology drug candidates through complementary in vitro assays and in vivo models to better understand their potential clinical applications.
List view / Grid view
Profiling oncology drug candidates through complementary in vitro assays and in vivo models to better understand their potential clinical applications.
This whitepaper describes the automated culturing of hiPSC-derived cells for high-throughput phenotypic screening, using validated phenotypic assays.
Analysis reveals people taking nucleoside reverse transcriptase inhibitors are significantly less likely to develop dry macular degeneration, a leading cause of age-related vision loss.
A new phenotype-based compound screening technology, called DeepCE, identified 10 compounds that could be repurposed for COVID-19.
The N439K mutation improves the interaction between SARS-CoV-2 Spike protein and the viral receptor ACE2 and eludes antibody-mediated immunity, say investigators.
In this whitepaper we explore some of the major bottlenecks in the development lifecycle and the current barriers to effective digital transformation.
28 January 2021 | By Eurofins DiscoverX & Sanford Burnham Prebys Discovery
In this on-demand webinar industry experts discuss how the InCELL Pulse technology provides a valuable tool for the discovery and characterisation of novel SHP2 inhibitors.
Learn how Simple Western automated immunoassays screen degraders and IMiD compounds to quantify degradation activity, providing accurate DC50 and Dmax values.
The lead candidate, ADG2, was able to neutralise SARS-CoV and various strains of SARS-CoV-2, including those that are resistant to currently available antibody treatments.
Researchers have discovered that giving L-tyrosine and PCS to mice prevents lung inflammation and an allergic asthma response.
A team has developed a new way to discover peptide therapeutics that inhibit HDAC enzymes and are effective against cancer.
In murine models of COVID-19, researchers found that non-steroidal anti-inflammatory drugs (NSAIDs) can suppress the inflammatory response and production of antibodies.
CAR T cells modified to recognise CEACAM7 were able to eliminate pancreatic ductal adenocarcinoma cells in a late-stage model without toxic effects on healthy tissue.
Identifying allosteric modulators and biased agonists for clinically relevant GPCRs. Case Studies using Eurofins Discovery’s GPCR product solutions.
The effect of various ion pairing reagents (amines and acidic counterions) on the LC/UV and LC/MS analysis of oligonucleotides (ONs) has been studied.